Ervaxx presents research identifying melanoma-specific Dark Antigens™ at SITC 2019.
CSO Dr. Ray Jupp presented data on Ervaxx’s lead program at the 34th Society for Immunotherapy of Cancer (SITC) annual meeting in National Harbor, MD, USA on Saturday 9th November 2019.
The poster, entitled “Discovery of immunogenic ERV-derived antigens as targets for melanoma”, is the first publication of data generated with Ervaxx’ proprietary EDAPT™ platform, supporting the development of a therapeutic, off-the-shelf vaccine for melanoma.
© Ervaxx Ltd 2019. Copies of this poster are for personal use only and may not be reproduced without written permission.